|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0013089,
umls-concept:C0030705,
umls-concept:C0085533,
umls-concept:C0144576,
umls-concept:C0178602,
umls-concept:C0184511,
umls-concept:C0205225,
umls-concept:C0392920,
umls-concept:C0746319,
umls-concept:C1274040,
umls-concept:C1705294
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2003-3-14
|
|
pubmed:abstractText |
This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BerryDonald ADA,
pubmed-author:CarpenterJohn TJT,
pubmed-author:CirrincioneConstance TCT,
pubmed-author:CooperM RobertMR,
pubmed-author:DemetriGeorge DGD,
pubmed-author:DugganDavid BDB,
pubmed-author:FlemingGiniG,
pubmed-author:FreiEmilE3rd,
pubmed-author:GoldsteinLori JLJ,
pubmed-author:HayesDaniel FDF,
pubmed-author:HendersonI CraigIC,
pubmed-author:HollandJames FJF,
pubmed-author:IngleJames NJN,
pubmed-author:MartinoSilvanaS,
pubmed-author:MussHyman BHB,
pubmed-author:NortonLarryL,
pubmed-author:SchilskyRichard LRL,
pubmed-author:TkaczukKatherine HKH,
pubmed-author:WoodWilliam CWC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
976-83
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:12637460-Adult,
pubmed-meshheading:12637460-Aged,
pubmed-meshheading:12637460-Antibiotics, Antineoplastic,
pubmed-meshheading:12637460-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:12637460-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12637460-Breast Neoplasms,
pubmed-meshheading:12637460-Disease-Free Survival,
pubmed-meshheading:12637460-Dose-Response Relationship, Drug,
pubmed-meshheading:12637460-Doxorubicin,
pubmed-meshheading:12637460-Female,
pubmed-meshheading:12637460-Humans,
pubmed-meshheading:12637460-Lymphatic Metastasis,
pubmed-meshheading:12637460-Middle Aged,
pubmed-meshheading:12637460-Paclitaxel,
pubmed-meshheading:12637460-Proportional Hazards Models,
pubmed-meshheading:12637460-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
|
pubmed:affiliation |
University of California at San Francisco, San, Francisco, CA 94143, USA. craig.henderson@accessoncology.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|
